PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Meta Expands AI Training With Employee Activity Tracking Tools 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SAN DIEGO, March 27, 2017 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company’s scheduled presentations at two upcoming investor conferences in New York:
- H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3.
- 16th Annual Needham Healthcare Conference at 3:00 p.m. ET on Tuesday, April 4.
Webcasts of both conference presentations will be available in the Investors section of the company’s website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
